Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Provention Bio Appoints Clinical Development SVP | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

Provention Bio Appoints Clinical Development SVP

Dr. Kell will lead the PRV-031 program, including the oversight of the Phase III PROTECT study and support of regulatory submissions

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sherron Kell, MD, MPH has been appointed senior vice president of Clinical Development at Provention Bio, Inc., a clinical stage biopharmaceutical company. Dr. Kell will lead the PRV-031 (teplizumab) program, including the oversight of the Phase III PROTECT study and clinical support of anticipated regulatory submissions, and will report to Dr. Eleanor Ramos, chief medical and operating officer.

PRV-031 (teplizumab) is an anti-CD3 monoclonal antibody in development for the interception and prevention of clinical type 1 diabetes (T1D).  PRV-031 (teplizumab) has been granted Breakthrough Therapy Designation for the prevention or delay of clinical T1D in individuals at-risk of developing the disease and orphan designation for newly diagnosed T1D.

“The addition of Sherron further enhances our leadership team during a transformational time for Provention,” stated Ashleigh Palmer, chief executive officer of Provention Bio. “Sherron’s expertise and extensive clinical development experience will be invaluable as we execute our clinical and regulatory strategy for PRV-031 (teplizumab) for the interception and prevention of T1D.”

Dr. Kell most recently served as vice president at Impax Pharmaceuticals, now Amneal Pharmaceuticals, overseeing Clinical R&D, Medical Affairs and the Pharmacovigilance and Drug Safety departments across all stages of clinical studies. Previously, she was senior director, Clinical R&D at Johnson & Johnson, and Scientific Director at Novartis Pharmaceuticals.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters